NDAORALTABLET
Approved
Oct 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMVAZ (amlodipine maleate) is an oral tablet small-molecule calcium channel blocker approved in 2003 for cardiovascular indications, primarily hypertension and angina. The drug works by relaxing vascular smooth muscle and reducing peripheral vascular resistance. It is a mature, widely-used antihypertensive with established safety and efficacy across multiple patient populations.
LOE Approaching
With LOE approaching, the AMVAZ brand team is likely in defensive/transition mode, managing declining market share against generic competition and focusing on retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects
Started May 2018
36 enrolled
Hypertension
Career Relevance
Working on AMVAZ offers limited growth potential given its LOE-approaching lifecycle; roles are primarily focused on defending market share, managing generic conversion, and optimizing profitability. Career advancement would typically require transition to growth-stage products or lateral movement into strategic planning roles.
Brand Manager
Worked on AMVAZ at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.